IPSEN Research and Development Expenses 2016-2024 | IPSEY

IPSEN research and development expenses for the twelve months ending December 31, 2024 were $0M, a 0% increase year-over-year.

  • IPSEN annual research and development expenses for 2024 were $0.743B, a 10.85% increase from 2023.
  • IPSEN annual research and development expenses for 2023 were $0.67B, a 42.86% increase from 2022.
  • IPSEN annual research and development expenses for 2022 were $0.469B, a 7.43% decline from 2021.

IPSEN Research and Development Expenses 2016-2024 | IPSEY

  • IPSEN annual research and development expenses for 2024 were $0.743B, a 10.85% increase from 2023.
  • IPSEN annual research and development expenses for 2023 were $0.67B, a 42.86% increase from 2022.
  • IPSEN annual research and development expenses for 2022 were $0.469B, a 7.43% decline from 2021.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$76.3B
Zoetis (ZTS)$66.2B
Takeda Pharmaceutical (TAK)$45.9B
Daiichi Sankyo, - (DSNKY)$45.5B
BeOne Medicines - (ONC)$32.3B
Sandoz Group AG (SDZNY)$25B
Summit Therapeutics (SMMT)$19.5B
Merck (MKKGY)$16.7B
Shionogi (SGIOY)$14.2B
United Therapeutics (UTHR)$13.2B
Neurocrine Biosciences (NBIX)$13.1B
Orion OYJ (ORINY)$11B
Stevanato Group S.p.A (STVN)$7.5B
Corcept Therapeutics (CORT)$7.5B
Madrigal Pharmaceuticals (MDGL)$7.4B
Grifols, S.A (GRFS)$6.8B
Ionis Pharmaceuticals (IONS)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.4B
Hypermarcas (HYPMY)$3.1B
Crinetics Pharmaceuticals (CRNX)$2.9B
Catalyst Pharmaceuticals (CPRX)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
NewAmsterdam Pharma (NAMS)$2.5B
Centessa Pharmaceuticals (CNTA)$2.1B
Ocular Therapeutix (OCUL)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B
Endo (NDOI)$1.6B